Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data sets appear to meet or exceed initial expectationsEarly signs of potential benefit emerge with some patients demonstrating Stable Disease NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announces financial results for the fourth quarter and fiscal year ended December 31, 2024 and provides a corporate update. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, "We continue

Meet with Indaptus Therapeutics' CEO Jeffrey MecklerRegister at INDP-KEYS.TribePublic.com NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) announces that Indaptus' CEO, Jeffrey Meckler, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Keys To The Kingdom: Unlocking The Power Of Your Immune System." The Event is scheduled to begin at 9:00am pacific/12:00pm eastern on Monday, March 17, 2025. To register to join the complimentary event, please visit the Tribe Public LLC at INDP-KEYS.TribePublic.com. Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at research@tribepublic.com or sha

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) – two diseases that continue to pose major global health challenges. The patents also extend to combination therapies with a variety of both approved and investigational treatments. Dr. Michael Newman, Founder and Chief Scientific Officer

HC Wainwright & Co. resumed coverage of Indaptus Therapeutics with a rating of Buy and set a new price target of $15.00

Maxim Group upgraded Indaptus Therapeutics from Hold to Buy and set a new price target of $16.00

4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

EFFECT - Indaptus Therapeutics, Inc. (0001857044) (Filer)

8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)

POS AM - Indaptus Therapeutics, Inc. (0001857044) (Filer)

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn. Indaptus Therapeutics emerges from over a century of groundbreaking advancements in immunotherapy and has built an approach that is designed to stimulate a broad acting effect on the immune sy

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. "We continue to be encouraged by early results from our first cohort of patients in the INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors.  As we recently reported and presented at the Society for Immunology in Cancer (SITC) conference, all four first cohort patients have maintained stable disease since receiving their single dose and presented evidence of immune activation, along with short-lived adverse events consistent with Decoy20's mech

NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. "We have recently announced the completion of the first cohort of patients in our INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors and receipt of authorization from the Safety Review Committee to advance into the second cohort. As previously announced, we are pleased to observe evidence of immune activation, along with short-lived adverse events consistent with Decoy20's mechanism of action," said Jeffrey Meckler, Chief Executive Officer of Indapt

Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data sets appear to meet or exceed initial expectationsEarly signs of potential benefit emerge with some patients demonstrating Stable Disease NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announces financial results for the fourth quarter and fiscal year ended December 31, 2024 and provides a corporate update. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, "We continue

Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus' broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 Indaptus Therapeutics Management will hold a conference call on October 22, 2024 at 4:30PM ET to discuss the agreement and future plans NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced a clinical supply agreement with BeiGene. Building on Indaptus' preclinical observation that Decoy20, when combined with a PD-1 inhibitor, induced complete

Company Remains On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022 NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), today announces financial results for the third quarter ended September 30, 2022 and provides a corporate update. "We continue to diligently prepare for the launch of our Phase 1 trial of Decoy20 for the treatment of solid tumors, while carefully managing our expenses," said Jeffrey Meckler, chief executive officer of Indaptus. "Once we have finalized the initiation process with our trial sites we will be prepared to speak more openly about progress, including tr

SC 13D/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

SC 13D - Indaptus Therapeutics, Inc. (0001857044) (Subject)

SC 13G/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)